Christopher A. Lipinski
Christopher A Lipinski is a medicinal chemist who has more than 34 years of experience working at Pfizer, Inc.[1] He is known for his "rule of five", an algorithm that predicts drug compounds that are likely to have oral activity.[1]
Lipinski received his PhD from the University of California, Berkeley in 1968 in physical organic chemistry.[2] The Advanced Drug Delivery Reviews article reporting his "rule of five" is one of the most cited publications in the journal's history.[1][3] In 2006 he received an honorary law degree from the University of Dundee and he has won various awards, including being the Society for Biomolecular Sciences' winner of the 2006 SBS Achievement Award for Innovation in HTS.[2][4]
References
- 1 2 3 "Melior Discovery scientific advisors". Retrieved 16 June 2015.
- 1 2 "scientific advisor". Retrieved 16 June 2015.
- ↑ Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. (2001). "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings". Advanced Drug Delivery Reviews 46 (1-3): 3–26. doi:10.1016/S0169-409X(00)00129-0. PMID 11259830.
- ↑ "Industry News: Dr. Christopher A. Lipinski Receives the 2006 SBS Achievement Award". Retrieved 16 June 2015.
|
This article is issued from Wikipedia - version of the Saturday, December 26, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.